Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities

Kras-driven non–small-cell lung cancers (NSCLCs) are a leading cause of death with limited therapeutic options. Many NSCLCs exhibit high levels of Ezh2, the enzymatic subunit of polycomb repressive complex 2 (PRC2). We tested Ezh2 inhibitors as single agents or before chemotherapy in mice with ortho...

Descripción completa

Detalles Bibliográficos
Autores principales: Serresi, Michela, Siteur, Bjorn, Hulsman, Danielle, Company, Carlos, Schmitt, Matthias J., Lieftink, Cor, Morris, Ben, Cesaroni, Matteo, Proost, Natalie, Beijersbergen, Roderick L., van Lohuizen, Maarten, Gargiulo, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279402/
https://www.ncbi.nlm.nih.gov/pubmed/30487290
http://dx.doi.org/10.1084/jem.20180801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279402/
https://www.ncbi.nlm.nih.gov/pubmed/30487290
http://dx.doi.org/10.1084/jem.20180801

Ejemplares similares